Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 15/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838900 | 0.86 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL27118576 | 0.82 | SLC10A2 (0.42) | SLC10A2GRM2MAPT | |
| SCHEMBL8026044 | 0.82 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL21585979 | 0.82 | SLC10A2 (0.39) | SLC10A2GRM2MAPT | |
| SCHEMBL30728273 | 0.82 | SLC10A2 (0.42) | SLC10A2GAAMAPT | |
| SCHEMBL22286586 | 0.82 | SLC10A2 (0.39) | SLC10A2 | |
| SCHEMBL29384063 | 0.82 | SLC10A2 (0.39) | SLC10A2 | |
| SCHEMBL22286438 | 0.82 | SLC10A2 (0.39) | SLC10A2 | |
| SCHEMBL26986042 | 0.82 | SLC10A2 (0.42) | SLC10A2GAAMAPT | |
| SCHEMBL5228173 | 0.81 | SLC10A2 (0.42) | SLC10A2GRM2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | PHARMACIA CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | G.D. SEARLE LLC | 2002-12-05 | — | — | US | disclosed |
| WO-2002008211-A2 | BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | G.D. SEARLE, LLC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | SLC10A1, ABCB11, SLC10A2 | SLC10A2 3/4885GRM2 1229/4885PDE4A 3244/4885 |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885GRM2 835/4885PDE4A 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.